The FDA AIR introduces binary regulatory risk but is described as routine; the stock will likely trade on progress toward the 180-day response deadline and any pre-Q4 FDA meeting. Monitor cash runway closely — at $10M/quarter FCF burn, the $18.7M cash balance provides less than two quarters of liquidity without additional financing. The favorable Medicare LCD and strong clinical data provide a positive backdrop, but the stock remains a high-risk pre-revenue catalyst play.
Price Chart
Executive Summary
IMDX reported Q2 2026 revenue of $239K (GAAP net loss -$0.31/share), essentially pre-revenue as it awaits FDA authorization for GraftAssureDx. The FDA completed its initial substantive review and issued an Additional Information Request (AIR), which the company views as routine and expects to respond to within 180 days. A favorable Medicare LCD expansion and strong head-to-head clinical data support the commercial thesis, but cash burn ($10M FCF in Q2) and the binary FDA outcome keep the stock in a high-risk, catalyst-driven state.
Key Financial Metrics
Key Facts
- Q2 2026 revenue was $239,000, down 54% YoY from $518,000; essentially pre-revenue.
- GAAP net loss per share was -$0.31 vs -$0.30 in Q2 2025; Non-GAAP net loss per share was -$0.23.
- FDA completed initial substantive review of GraftAssureDx and issued an Additional Information Request (AIR); company must respond within 180 days.
- Cash, cash equivalents, and restricted cash fell to $18.7M from $29.4M at Q1 end; free cash flow was -$10M in Q2.
- Medicare (MolDX) issued a favorable local coverage decision expanding surveillance testing frequency and confirming reimbursement for treatment-response monitoring.
- Head-to-head data published in Clinical Chemistry showed 99.2% agreement with a leading NGS competitor; GraftAssure CM-Score showed 81% positive predictive value vs 54% benchmark.
- Weighted average shares outstanding rose to 36.8M from 32.0M YoY; pro-forma fully diluted count is 36.9M.
Financial Impact
Q2 2026 revenue $239,000 (down 54% YoY); GAAP net loss -$11.3M; operating cash burn -$9.3M; cash balance $18.7M provides runway into mid-2027 at current burn rate.
Risk Factors
- FDA AIR could lead to extended review timeline or denial of GraftAssureDx marketing authorization.
- Cash burn of ~$10M/quarter with only $18.7M on hand raises going-concern risk if FDA decision is delayed or negative.
- Revenue remains negligible ($239K) and dependent on FDA approval for commercialization; no material kitted product revenue expected until authorization.
- Share dilution continues (36.8M weighted avg shares, up 15% YoY) from pre-funded warrant exercises and equity issuances.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-036863 |
| Document: form8-k.htm | 0001493152-26-036863 |
| Document: 0001493152-26-036863-index-headers.html | 0001493152-26-036863 |
| Document: 0001493152-26-036863-index.html | 0001493152-26-036863 |
| Document: 0001493152-26-036863.txt | 0001493152-26-036863 |
| 8-K Data (Synthetic) | 0001493152-26-036863 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 10w ago | 8-K | $4.43 | awaiting T+60 | — | $2.93 (−33.86%) |
Mar 26, 2026 30w ago | Press Release | $3.56 $5.46 | ▲ +53.43% | ▲ +37.36% | $2.93 (−17.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers